Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue, FDA-approved in 2010 as Egrifta for one specific indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The trial evidence for that use is strong. It is not approved anywhere else in the world, has no trials in metabolically healthy adults, and is banned in tested sport by WADA.
Sermorelin is a synthetic fragment of natural GHRH, the hormone that tells the pituitary to release growth hormone. It was FDA-approved in 1990 as Geref for paediatric growth hormone deficiency, then withdrawn from the US market in 2008 for commercial, not safety, reasons. No regulator licenses it today. It now sells as a compounded "anti-ageing" injectable, untested in healthy adults at that scale.
Tesamorelin sits at grade B; Sermorelin at grade C. On evidence alone, Tesamorelin is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you", read both pages, then talk to a clinician.
The only FDA-approved indication, granted in November 2010 on the basis of the Theratechnologies Phase 3 programme (Falutz et al., NEJM 2007 and JAIDS 2010). For adults with HIV who have lipodystrophy and excess visceral abdominal fat. Mean visceral fat reduction in the pivotal trials was on the order of 15–18% over 26 weeks versus placebo.
Stanley TL et al., JAMA 2014, showed reductions in both visceral fat and liver fat fraction in adults with HIV and abdominal fat accumulation. A subsequent randomised trial in HIV-NAFLD (Stanley et al., Lancet HIV 2019) extended this finding. Not an FDA-approved indication, but the evidence base in this specific HIV sub-population is genuine.
In post-hoc analyses of the Phase 3 programme (Stanley et al., Clin Infect Dis 2012), people whose visceral fat fell in response to tesamorelin also saw improvements in triglycerides and adiponectin. Consistent with the mechanism. Still HIV-LD-specific.
FDA-approved in 1990 as Geref Diagnostic for the GHRH stimulation test in children with suspected growth hormone deficiency. Robust historical use; product no longer marketed.
FDA-approved as Geref for the treatment of children with idiopathic growth hormone deficiency. Documented growth response in trials; superseded by recombinant human GH (somatropin) on convenience and efficacy. Withdrawn from market 2008 for commercial reasons.
Small studies and review articles from the 2000s argued sermorelin could partially restore the diminished nocturnal GH pulse seen in older adults. Sample sizes are small, follow-up short, and no modern RCT has tested hard outcomes (body composition, function, cardiometabolic events) at scale.
The commonest adverse effects in the Phase 3 programme were injection-site reactions (redness, swelling, itching), arthralgia, myalgia, peripheral oedema and flushing, the usual class effects of pushing the GH/IGF-1 axis upwards. The more serious concerns are also axis-mediated: transient insulin resistance with modest increases in fasting glucose and HbA1c, fluid retention, carpal-tunnel-like symptoms, and the theoretical risk of accelerating active malignancy via IGF-1 (the label contraindicates use in active malignancy). The FDA label carries warnings on glucose intolerance and diabetes, acute critical illness, and hypersensitivity (including rare anaphylaxis). Tesamorelin is contraindicated in pregnancy, in disrupted hypothalamic–pituitary axis (e.g. hypophysectomy, hypopituitarism, pituitary tumour or surgery) and during acute critical illness. The IGF-1 elevation that does the work is the same axis implicated in malignancy if pushed chronically; the durations actually studied are short, a year or less in the main programme.
In the paediatric record, sermorelin was generally well tolerated. The commonest issues were local injection-site reactions (redness, swelling, pain), occasional flushing and headache, and rare cases of dysphagia or transient hyperactivity. Antibodies against sermorelin were detected in a minority of children on long-term therapy; clinical significance was unclear. Because sermorelin works through the body's own GH/IGF-1 axis, it shares the theoretical long-term concerns of any GH-raising therapy: potential effects on glucose tolerance, the theoretical concern that chronically elevated IGF-1 could accelerate growth of pre-existing cancers, and unknowns around long-term exposure in healthy adults who weren't the original target population. Pregnancy and breastfeeding: avoid. Compounded sermorelin from a 503A pharmacy is not FDA-reviewed for purity, potency or stability the way an approved drug is, and US compounding has had repeated quality incidents across drug categories. People with active malignancy, uncontrolled diabetes, severe respiratory or cardiac illness, or pituitary disease should not use it outside specialist care.
Tesamorelin sits at grade B; Sermorelin at grade C. On evidence alone, Tesamorelin is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you", read both pages, then talk to a clinician.
Pepwyse comparison pages are generated from the same structured data behind each peptide profile. Want a different head-to-head? Use the compare picker or ask Tesamorelin directly via the Ask-Peppy button. Not medical advice, see how we grade evidence.